MA47516A - Composition pharmaceutique - Google Patents

Composition pharmaceutique

Info

Publication number: MA47516A
Authority: MA; Morocco
Prior art keywords: pharmaceutical composition; pharmaceutical; composition
Prior art date: 2017-02-15

Application number

MA047516A

Other languages

English (en)

Inventor

Shinji Okada

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-15

Filing date

2018-02-14

Publication date

2021-03-31

2018-02-14 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2021-03-31 Publication of MA47516A publication Critical patent/MA47516A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MA047516A 2017-02-15 2018-02-14 Composition pharmaceutique MA47516A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2017026203		2017-02-15

Publications (1)

Publication Number	Publication Date
MA47516A true MA47516A (fr)	2021-03-31

Family

ID=63169269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047516A MA47516A (fr)	2017-02-15	2018-02-14	Composition pharmaceutique

Country Status (21)

Country	Link
US (2)	US11110062B2 (fr)
EP (1)	EP3583943B1 (fr)
JP (1)	JP6771594B2 (fr)
KR (2)	KR102323255B1 (fr)
CN (2)	CN117137915A (fr)
AU (1)	AU2018222163C1 (fr)
BR (1)	BR112019016764A2 (fr)
CA (1)	CA3053739C (fr)
DK (1)	DK3583943T3 (fr)
ES (1)	ES2991062T3 (fr)
FI (1)	FI3583943T3 (fr)
HU (1)	HUE068810T2 (fr)
MA (1)	MA47516A (fr)
MX (2)	MX2021007061A (fr)
MY (1)	MY194278A (fr)
PH (1)	PH12019501873A1 (fr)
PL (1)	PL3583943T3 (fr)
PT (1)	PT3583943T (fr)
SG (1)	SG11201907433TA (fr)
TW (1)	TWI702951B (fr)
WO (1)	WO2018151177A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3053739C (fr)	2017-02-15	2023-02-14	Taiho Pharmaceutical Co., Ltd.	Composition pharmaceutique
JP7074760B2 (ja) *	2017-09-08	2022-05-24	大鵬薬品工業株式会社	抗腫瘍剤及び抗腫瘍効果増強剤
MA53667A (fr)	2018-09-18	2021-07-28	Taiho Pharmaceutical Co Ltd	Polythérapie associant un composé d'acylthiourée et de l'abiratérone
CN115103834A (zh) *	2020-02-14	2022-09-23	大鹏药品工业株式会社	酰硫脲化合物的类缘物质
EP4181306A4 (fr)	2021-03-12	2025-01-22	Lg Energy Solution Ltd	Ensemble barre omnibus, bloc-batterie comprenant un ensemble barre omnibus, et véhicule comprenant un bloc-batterie
US20230114887A1 (en)	2021-10-12	2023-04-13	Lg Energy Solution, Ltd.	Battery pack and vehicle including the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5254541A (en) *	1991-11-15	1993-10-19	Merck Frosst Canada, Inc.	(Quinolin-2-ylmethoxy)indole/cyclodextrin complex
CN1154070A (zh) *	1994-05-27	1997-07-09	荷兰发马克有限公司	药物组合物
EP1243582A4 (fr)	1999-12-24	2003-06-04	Kirin Brewery	Quinoline, derives de la quinazoline et medicaments contenant ces substances
KR100589032B1 (ko)	2000-10-20	2006-06-14	에자이 가부시키가이샤	질소 함유 방향환 유도체
US7425564B2 (en)	2001-06-22	2008-09-16	Kirin Beer Kabushiki Kaisha	Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same
SE520606C2 (sv)	2001-06-26	2003-07-29	Flir Systems Ab	Förfarande för att åstadkomma en spegelyta, samt spegel med sådan spegelyta
JP2003238592A (ja)	2001-12-13	2003-08-27	Japan Tobacco Inc	組織及び血管の再生のための医薬及びその方法
CN1448053A (zh) *	2003-04-22	2003-10-15	西安敬业生物药物科技有限公司	甲基托布津包络物农药制剂
PT2210607E (pt)	2003-09-26	2012-01-31	Exelixis Inc	N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolina-4-ilpropil)oxi]quinolina-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida para o tratamento do cancro
AU2005217328B2 (en)	2004-02-27	2007-10-04	Eisai R & D Management Co., Ltd.	Novel pyridine derivative and pyrimidine derivative (2)
WO2005105044A1 (fr) *	2004-04-30	2005-11-10	Ranbaxy Laboratories Limited	Procede de fabrication d'un complexe d'inclusion de sulfonylurees presentant une solubilite aqueuse amelioree
WO2005121125A1 (fr)	2004-06-09	2005-12-22	Pfizer Inc.	Composes heteroaryle a liaison ether
US7173031B2 (en)	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
CN100448053C (zh) *	2004-08-31	2008-12-31	清华大学	含有屏蔽掩膜支撑体的有机电致发光器件及其制备方法
AU2006229343A1 (en)	2005-03-28	2006-10-05	Kirin Pharma Kabushiki Kaisha	Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JP2008537748A (ja)	2005-04-06	2008-09-25	エクセリクシス、インコーポレイテッド	ｃ−Ｍｅｔモジュレーター及び使用方法
US7728017B2 (en)	2005-11-30	2010-06-01	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Met and uses thereof
KR20100089090A (ko)	2007-10-25	2010-08-11	아스트라제네카 아베	세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
CN101491240A (zh) *	2008-01-25	2009-07-29	国家农产品保鲜工程技术研究中心（天津）	提高纳他霉素作用效率的方法
CA2713930A1 (fr)	2008-01-29	2009-08-06	Eisai R & D Management Co., Ltd.	Utilisation combinee d'un inhibiteur de l'angiogenese et d'un taxane
AR070861A1 (es)	2008-03-06	2010-05-12	Genentech Inc	Uso de terapia de combinacion con antagonistas de c-met y egfr
EP2287155B1 (fr)	2008-04-10	2013-07-17	Taiho Pharmaceutical Co., Ltd.	Composé acylthiourée ou son sel et leur utilisation
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CA2723617A1 (fr)	2008-05-14	2009-11-19	Amgen Inc.	Combinaisons d'inhibiteurs de vegf(r) et d'inhibiteurs du facteur de croissance d'hepatocyte (c-met) pour le traitement du cancer
UY32049A (es)	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
PE20160116A1 (es) *	2008-11-15	2016-03-09	Melinta Therapeutics Inc	Composiciones antimicrobianas
MX2011008584A (es)	2009-02-12	2012-01-27	Kyowa Hakko Kirin Co Ltd	Composiciones combinacionales y metodos para el tratamiento del cancer.
CN101926808A (zh)	2009-06-25	2010-12-29	积华药业有限公司	氨基葡萄糖制剂
CN102812027B (zh)	2010-02-03	2015-01-07	因西特公司	作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪
NZ703111A (en)	2010-05-17	2016-07-29	Incozen Therapeutics Pvt Ltd	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CN102274189A (zh) *	2011-07-21	2011-12-14	瑞普（天津）生物药业有限公司	一种含有癸氧喹酯的干混悬剂组方及其制备方法
US9447065B2 (en)	2011-10-18	2016-09-20	Raqualia Pharma Inc.	Pharmaceutical composition
TWI594986B (zh)	2011-12-28	2017-08-11	Taiho Pharmaceutical Co Ltd	Antineoplastic agent effect enhancer
RU2494470C1 (ru)	2012-04-04	2013-09-27	Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент")	Способ лечения фиброза легких
WO2015007760A1 (fr) *	2013-07-19	2015-01-22	Boehringer Ingelheim Vetmedica Gmbh	Composition pharmaceutique aqueuse liquide contenant des dérivés de cyclodextrine éthérifiés conservés
US9149471B2 (en)	2013-09-30	2015-10-06	National University Corporation Tokyo University Of Agriculture And Technology	Therapeutic agent for osteoporosis
KR20160119867A (ko)	2014-03-05	2016-10-14	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
CN114224894B (zh)	2014-12-03	2025-01-07	奥克兰联合服务有限公司	用于治疗癌症的激酶抑制剂前药
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
JP2016196411A (ja)	2015-03-04	2016-11-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
DK3290405T3 (da)	2015-04-30	2021-03-22	Taiho Pharmaceutical Co Ltd	Mesylsyresalt af acylthioureaforbindelse, krystal deraf og fremgangsmåder til fremstilling deraf
ES2928684T3 (es)	2015-06-25	2022-11-21	Taiho Pharmaceutical Co Ltd	Agente terapéutico para la fibrosis
JP6804832B2 (ja)	2015-07-21	2020-12-23	東芝ライフスタイル株式会社	冷蔵庫
CN106551911A (zh)	2015-09-21	2017-04-05	天津市汉康医药生物技术有限公司	一种稳定的乐伐替尼药物组合物及其制备方法
CA3053739C (fr)	2017-02-15	2023-02-14	Taiho Pharmaceutical Co., Ltd.	Composition pharmaceutique

2018
- 2018-02-14 CA CA3053739A patent/CA3053739C/fr active Active
- 2018-02-14 PL PL18755023.1T patent/PL3583943T3/pl unknown
- 2018-02-14 US US16/485,971 patent/US11110062B2/en active Active
- 2018-02-14 KR KR1020197023592A patent/KR102323255B1/ko active IP Right Grant
- 2018-02-14 HU HUE18755023A patent/HUE068810T2/hu unknown
- 2018-02-14 SG SG11201907433TA patent/SG11201907433TA/en unknown
- 2018-02-14 PT PT187550231T patent/PT3583943T/pt unknown
- 2018-02-14 TW TW107105612A patent/TWI702951B/zh active
- 2018-02-14 CN CN202311298292.7A patent/CN117137915A/zh active Pending
- 2018-02-14 CN CN201880012000.XA patent/CN110312511B/zh active Active
- 2018-02-14 AU AU2018222163A patent/AU2018222163C1/en active Active
- 2018-02-14 EP EP18755023.1A patent/EP3583943B1/fr active Active
- 2018-02-14 MA MA047516A patent/MA47516A/fr unknown
- 2018-02-14 WO PCT/JP2018/005140 patent/WO2018151177A1/fr unknown
- 2018-02-14 MY MYPI2019004652A patent/MY194278A/en unknown
- 2018-02-14 MX MX2021007061A patent/MX2021007061A/es unknown
- 2018-02-14 JP JP2018568583A patent/JP6771594B2/ja active Active
- 2018-02-14 ES ES18755023T patent/ES2991062T3/es active Active
- 2018-02-14 FI FIEP18755023.1T patent/FI3583943T3/fi active
- 2018-02-14 MX MX2019009717A patent/MX2019009717A/es unknown
- 2018-02-14 DK DK18755023.1T patent/DK3583943T3/da active
- 2018-02-14 KR KR1020217035697A patent/KR20210135354A/ko not_active Application Discontinuation
- 2018-02-14 BR BR112019016764-1A patent/BR112019016764A2/pt active IP Right Grant
2019
- 2019-08-13 PH PH12019501873A patent/PH12019501873A1/en unknown
2021
- 2021-06-15 US US17/347,989 patent/US12144892B2/en active Active

Also Published As

Publication number	Publication date
ES2991062T3 (es)	2024-12-02
EP3583943A4 (fr)	2020-12-30
US20200060973A1 (en)	2020-02-27
HUE068810T2 (hu)	2025-01-28
US12144892B2 (en)	2024-11-19
RU2019125612A (ru)	2021-03-16
MX2019009717A (es)	2019-10-02
FI3583943T3 (fi)	2024-10-29
CN117137915A (zh)	2023-12-01
TWI702951B (zh)	2020-09-01
EP3583943A1 (fr)	2019-12-25
KR20190113831A (ko)	2019-10-08
PL3583943T3 (pl)	2024-11-25
AU2018222163C1 (en)	2021-08-12
DK3583943T3 (da)	2024-10-14
CA3053739C (fr)	2023-02-14
CN110312511A (zh)	2019-10-08
US20210308056A1 (en)	2021-10-07
EP3583943B1 (fr)	2024-09-18
CN110312511B (zh)	2023-10-27
PT3583943T (pt)	2024-10-15
WO2018151177A1 (fr)	2018-08-23
AU2018222163A1 (en)	2019-09-05
BR112019016764A2 (pt)	2020-03-31
KR102323255B1 (ko)	2021-11-08
MX2021007061A (es)	2022-10-07
SG11201907433TA (en)	2019-09-27
AU2018222163B2 (en)	2021-01-28
TW201836608A (zh)	2018-10-16
JPWO2018151177A1 (ja)	2019-11-07
JP6771594B2 (ja)	2020-10-21
RU2019125612A3 (fr)	2021-03-16
CA3053739A1 (fr)	2018-08-23
KR20210135354A (ko)	2021-11-12
US11110062B2 (en)	2021-09-07
PH12019501873A1 (en)	2020-06-15
MY194278A (en)	2022-11-25

Publication	Publication Date	Title
KR102281667B9 (ko)	2024-01-08	아트로핀 약학 조성물 (atropine pharmaceutical compositions)
HK1243650A1 (zh)	2018-07-20	包含美洛昔康的藥物組合物
DK3529248T3 (da)	2020-09-14	Farmaceutiske sammensætninger
EP3454899C0 (fr)	2024-03-20	Composition pharmaceutique
LT3655038T (lt)	2025-02-10	Farmacinė kompozicija
MA47816A (fr)	2020-01-15	Composition pharmaceutique comprenant du sélexipag
EP3641771A4 (fr)	2020-12-16	Compositions pharmaceutiques
EP3452075A4 (fr)	2019-12-11	Composition pharmaceutique ophtalmique
DK3532029T3 (da)	2021-06-07	Flydende farmaceutisk sammensætning
DK3634377T3 (da)	2021-08-30	Farmaceutisk formulering
MA43705A (fr)	2018-11-28	Formulation pharmaceutique
EP3603642A4 (fr)	2020-09-02	Préparation pharmaceutique
DK3529240T3 (da)	2020-09-07	Farmaceutiske forbindelser
MA47516A (fr)	2021-03-31	Composition pharmaceutique
IL283900A (en)	2021-07-29	Pharmaceutical combinations
MA49837A (fr)	2020-06-17	Compositions pharmaceutiques
DK3672631T5 (da)	2024-08-26	Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
DK3313370T3 (da)	2021-03-29	Oftalmologisk farmaceutisk sammensætning
EP3646866A4 (fr)	2021-03-24	Préparation pharmaceutique
EP3727485C0 (fr)	2023-07-26	Composition pharmaceutique
EP3383371A4 (fr)	2019-07-24	Formulation pharmaceutique
SMT202400478T1 (it)	2025-01-14	Composizione farmaceutica
DK3601277T3 (da)	2024-01-15	Farmaceutisk formulering
MA45126A (fr)	2021-04-14	Formulation pharmaceutique antifongique
EP3459369A4 (fr)	2019-12-11	Composition pharmaceutique utilisant la souchelactobacillus